European Marketing Authorisation Opinion

 22 May 2020

ECO Animal Health Group plc

(the "Group")

(AIM: EAH)

EUROPEAN POSITIVE OPINION FOR AIVLOSIN® IN PIGS

ECO Animal Health Group plc (the "Group") is pleased to announce that its subsidiary ECO Animal Health Limited (ECO) has received a positive opinion from the European Medicines Agency (EMA) for the use of Aivlosin® 625 mg/g Water Soluble Granules (WSG) for the treatment and metaphylaxis (disease control) of Mycoplasma hyopneumoniae in pigs.  

Mycoplasma hyopneumoniae is the most common primary pathogen in pig respiratory disease and is a key instigator of secondary bacterial and viral pathogens.

Aivlosin®, ECO's patented antimicrobial, is used under veterinary prescription for the treatment of a variety of economically important respiratory and enteric (gut) diseases in poultry and pigs.

The European Commission is expected to issue a marketing authorisation within two months of the publication of a positive opinion.

Marc Loomes, CEO, commented: "Aivlosin® offers a safe and highly effective medication for Mycoplasma infections. This positive opinion is significant, not only in the EU which has fifteen per cent of the world's pigs but for other large international swine markets as this indication is rolled out. Whilst we bring forward our new product development programme, particularly around vaccines, it is important to note that Aivlosin® 's approved usage continues to expand across multiple treatment areas and markets."

The information contained within this announcement is deemed by the Group to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 ("MAR"). Upon the publication of this announcement via a Regulatory Information Service ("RIS"), this inside information is now considered to be in the public domain.

Contacts: 

ECO Animal Health Group plc ("ECO" or "the "GROUP") researches, develops and commercialises products for livestock. Our business strategy is to generate shareholder value by achieving the maximum sales potential from the existing product portfolio whilst investing in Research and Development ("R&D") for new products, particularly vaccines, and seeking to in-license new products.